Skip to main content

Table 3 Estimated study- treatment-, time- and individual covariate- effects using a fixed effect model

From: Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations

Parameters mean sd 2.5% 97.5%
α 1 4.91* 0.71 3.61 6.42
α 2 5.77* 0.72 4.45 7.29
γ S 3 (Study 3-1) 0.246 0.537 -0.742 1.371
γ S 4 (Study 4-1) 0.572 0.584 −0.547 1.719
γ S 5 (Study 5-1) −0.505 0.367 −1.216 0.222
γ 2 (AQ) −0.402 0.434 −1.218 0.481
γ 3 (AMLM) 1.212 0.936 −0.443 3.24
γ 4 (ASCD) −1.514* 0.682 −2.85 −0.186
γ 5 (ASSP) −0.109 0.465 −0.989 0.844
γ 6 (DHPP) 2.353* 0.852 0.924 4.288
γ D 21 (Day 21–14) −2.121* 0.459 −3.112* −1.298
γ D 28 (Day 28–14) −2.036* 0.467 −3.030* −1.194
Weight 0.218 0.360 −0.478 0.933
Gender −0.154 0.234 −0.615 0.298
Age 0.189 0.505 −0.896 1.067
Parasitaemia Day 0 −0.171 0.352 −0.872 0.506
Parasitaemia Day 3 0.085 0.669 −1.083 1.542
Expected children 795 746 732  
Missing 49 14 59 122 (15)
Fully observed 746 732 687  
  1. sd: standard deviation, 2.5% and 97.5% : percentiles of the posterior distributions. Study reference: Study 1; Treatment reference: ASAQ; Day reference: Day 14. *: significant effect at the 0.05% level.